QULIPTA Drug Insight

“QULIPTA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about QULIPTA for chronic pain in the seven major markets. A detailed picture of the QULIPTA for chronic pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the QULIPTA for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the QULIPTA market forecast analysis for chronic pain in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

Atogepant (approved as QULIPTA for preventive treatment of episodic migraine) is an orally administered, small-molecule Calcitonin Gene-related Peptide (CGRP) receptor antagonist (Gepant) developed explicitly for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks, and selective CGRP receptor antagonists confer clinical benefits in migraine.

A Pivotal Phase III study evaluating atogepant in adult patients with chronic migraine was completed and met its primary endpoint. In June 2022, AbbVie submitted a supplemental New Drug Application (sNDA) for atogepant to FDA to support the preventive treatment of chronic migraine in adults.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the QULIPTA description, mechanism of action, dosage and administration, research and development activities in chronic pain.
Elaborated details on QULIPTA regulatory milestones and other development activities have been provided in this report.
The report also highlights the QULIPTA research and development activities in chronic pain across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around QULIPTA.
The report contains forecasted sales of for chronic pain till 2032.
Comprehensive coverage of the late-stage emerging therapies for chronic pain.
The report also features the SWOT analysis with analyst views for QULIPTA in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

QULIPTA Analytical Perspective by DelveInsight

In-depth QULIPTA Market Assessment

This report provides a detailed market assessment of QULIPTA for chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

QULIPTA Clinical Assessment

The report provides the clinical trials information of QULIPTA for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence QULIPTA dominance.
Other emerging products for chronic pain are expected to give tough market competition to QULIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of QULIPTA in chronic pain.
Our in-depth analysis of the forecasted sales data of QULIPTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the QULIPTA in chronic pain.

Key Questions

What is the product type, route of administration and mechanism of action of QULIPTA?
What is the clinical trial status of the study related to QULIPTA in chronic pain and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the QULIPTA development?
What are the key designations that have been granted to QULIPTA for chronic pain?
What is the forecasted market scenario of QULIPTA for chronic pain?
What are the forecasted sales of QULIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to QULIPTA for chronic pain?
Which are the late-stage emerging therapies under development for the treatment of chronic pain?